Clinical Trials Logo

Clinical Trial Summary

The investigators propose to study novel targets of rituximab in podocytes, with a particular focus on recurrent focal segmental glomerulosclerosis (FSGS). The proposed study has strong clinical implications, since it may extend the approved indications for rituximab treatment to recurrent FSGS as well as to other proteinuric diseases. Furthermore, it will offer new insights into the role of sphyngomyelin related enzymes in podocyte function in health and disease, thus allowing the identification of novel targets for antiproteinuric drug development. Finally, the proposed study offers the opportunity to identify a correlation between the patient's specific clinical outcome and the experimental results obtained after exposing podocytes to patient sera in the presence or absence of rituximab. Therefore, it may lead to the development of an assay for the pre-transplant identification of patients at high-risk for recurrent disease and, among them, may allow the identification of those patients that will respond to rituximab.


Clinical Trial Description

A total of 60 patients will be enrolled in the study. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01164098
Study type Interventional
Source University of Miami
Contact
Status Terminated
Phase Phase 3
Start date February 2012
Completion date October 2016

See also
  Status Clinical Trial Phase
Completed NCT03510286 - Validation of a PrCr Dipstick Diagnostic Test in Ghana
Completed NCT05086549 - An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
Terminated NCT04051957 - Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury Phase 2
Terminated NCT02057523 - Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients Phase 4
Completed NCT02232763 - Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria Phase 3
Completed NCT02226055 - An Investigation Into the Cardiovascular Risk and Aetiology of CKDu in Sri Lanka N/A
Completed NCT00493727 - Use of Mucomyst to Ameliorate Oxidant Stress in Diabetics With Proteinuria N/A
Active, not recruiting NCT00565396 - Effectiveness Study on Fosinopril and/or Losartan in Patients With Chronic Kidney Disease Stage 3 N/A
Recruiting NCT05759754 - Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease N/A
Withdrawn NCT02882373 - Arginine in Treating Patients With Anti-VEGF Induced Kidney Injury Phase 2
Completed NCT02327403 - Belatacept Conversion in Proteinuric Kidney Transplant Recipients Phase 2
Recruiting NCT01773382 - The Effects of Weight Reduction in IgA Nephropathy N/A
Completed NCT00915200 - N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy Phase 2
Completed NCT01029002 - The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease Phase 3
Withdrawn NCT00541619 - Sympathetic Overactivity in Essential Hypertension N/A
Withdrawn NCT00392132 - Impact of Screening Patients With HIV for Kidney Disease
Terminated NCT00001978 - Determination of Kidney Function
Recruiting NCT05457283 - A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria Phase 3
Completed NCT04874753 - The Effect of COVID-19 Pandemia on Follow up of Patients With Chronic Kidney Disease
Recruiting NCT02972346 - Availability Study of ACTH to Treat Children SRNS/SDNS N/A